…
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, South-East Asia, and internationally. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides health and wellness products under the EZZ brand. It also offers its products online. The company was incorporated in 2015 and is based in Lidcombe, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
EZZ Life Science Holdings Ltd (ASX: EZZ) is an Australian-listed company that develops, markets and distributes nutraceutical and health-wellness products. Long-term growth drivers include ageing populations and rising preventive-health demand, together with potential gains from expanding distribution channels and broadening the product portfolio that may support revenue diversification.
Important risks include regulatory and compliance exposure in the dietary-supplement sector, strong competitive pressure, execution and scaling risk for distribution and new products, and potential liquidity or financing constraints common to small-cap consumer-health companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.41M | 10.59M | 9.96M | 4.90M | 1.78M |
| Net income | -5.32M | 6.73M | 6.96M | 3.63M | 1.31M |
| Selling general administrative | - | 3.60M | 1.26M | 1.15M | 0.90M |
| Selling and marketing expenses | - | 32.27M | 37.23M | 20.56M | 2.97M |
| Gross profit | 25.77M | 49.72M | 50.95M | 27.20M | 7.51M |
| Reconciled depreciation | - | 0.51M | 0.39M | 0.18M | 0.12M |
| Ebit | 43.40M | 10.59M | 9.98M | 4.91M | 1.78M |
| Ebitda | 43.88M | 11.10M | 10.38M | 5.09M | 1.90M |
| Depreciation and amortization | 0.49M | 0.51M | 0.39M | 0.18M | 0.12M |
| Operating income | 43.40M | 9.93M | 9.72M | 4.62M | 1.64M |
| Other operating expenses | 52.89M | 56.94M | 56.73M | 32.53M | 13.38M |
| Interest expense | 0.02M | 0.03M | 0.02M | 0.01M | 0.00M |
| Tax provision | - | 3.86M | 2.99M | 1.27M | 0.47M |
| Interest income | - | 0.42M | 0.20M | 0.24M | 0.00M |
| Net interest income | - | 0.39M | 0.17M | 0.03M | -0.00M |
| Income tax expense | -1.09M | 3.86M | 2.99M | 1.27M | 0.47M |
| Total revenue | 46.28M | 66.87M | 66.44M | 37.14M | 15.02M |
| Total operating expenses | 32.38M | 39.79M | 41.23M | 22.59M | 5.87M |
| Cost of revenue | 20.51M | 17.15M | 15.50M | 9.94M | 7.51M |
| Total other income expense net | -49.81M | 0.66M | 0.24M | 0.29M | 0.14M |
| Net income from continuing ops | - | 6.73M | 6.96M | 3.63M | 1.31M |
| Net income applicable to common shares | - | 6.73M | 6.96M | 3.63M | 1.31M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 27.64M | 33.96M | 25.55M | 17.64M | 14.27M |
| Intangible assets | 0.03M | 0.03M | - | 0.02M | 0.02M |
| Other current assets | 7.25M | 0.89M | 1.81M | 0.94M | 0.90M |
| Total liab | 3.15M | 5.87M | 4.23M | 3.06M | 2.88M |
| Total stockholder equity | 24.49M | 28.09M | 21.32M | 14.58M | 11.39M |
| Other current liab | 0.58M | - | 0.04M | 0.36M | 0.32M |
| Common stock | 11.40M | - | 6.52M | 6.00M | 5.82M |
| Capital stock | - | 8.74M | - | 6.00M | 5.82M |
| Retained earnings | 13.07M | 19.32M | 14.79M | 8.58M | 5.56M |
| Other liab | - | - | - | - | 0.06M |
| Other assets | - | - | - | 0.01M | 0.13M |
| Cash | 9.72M | 20.85M | 19.02M | 13.83M | 10.46M |
| Total current liabilities | 2.98M | 5.73M | 4.18M | 2.93M | 2.82M |
| Current deferred revenue | - | - | 1.20M | - | - |
| Net debt | -9.25M | - | -18.90M | - | -10.36M |
| Short term debt | 0.35M | - | 0.12M | 0.00M | 0.10M |
| Short long term debt total | 0.48M | - | 0.12M | - | 0.10M |
| Other stockholder equity | - | - | 0.00M | 0.00M | - |
| Property plant equipment | - | - | - | 0.60M | 0.15M |
| Total current assets | 25.95M | 33.04M | 24.91M | 17.01M | 13.97M |
| Net tangible assets | - | - | - | 14.56M | 11.37M |
| Net receivables | 4.96M | 4.47M | 2.67M | 1.39M | 2.29M |
| Inventory | 4.02M | 2.43M | 1.40M | 0.85M | 0.31M |
| Accounts payable | 2.05M | 3.46M | 2.82M | 2.14M | 2.39M |
| Accumulated other comprehensive income | 0.02M | - | 0.02M | - | - |
| Non currrent assets other | - | - | 0.02M | - | - |
| Non current assets total | 1.69M | 0.92M | 0.64M | 0.63M | 0.29M |
| Capital lease obligations | - | 0.30M | - | 0.48M | 0.10M |
| Long term debt total | - | - | - | 0.12M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.55M | -0.44M | -0.10M | -0.01M |
| Change to liabilities | - | - | - | -0.16M | 0.88M |
| Total cashflows from investing activities | -0.65M | -0.55M | -0.44M | -0.10M | -0.01M |
| Net borrowings | - | - | - | -0.16M | -0.10M |
| Total cash from financing activities | -1.26M | -2.17M | -0.58M | -0.76M | -0.28M |
| Change to operating activities | - | - | - | -0.02M | -0.48M |
| Net income | -5.32M | 6.73M | 6.96M | 3.63M | 1.31M |
| Change in cash | -11.13M | 1.83M | 5.19M | 3.37M | 1.61M |
| Begin period cash flow | 20.85M | 19.02M | 13.83M | 10.46M | 8.85M |
| End period cash flow | 9.72M | 20.85M | 19.02M | 13.83M | 10.46M |
| Total cash from operating activities | -8.76M | 4.35M | 6.14M | 4.01M | 1.90M |
| Issuance of capital stock | - | - | 0.85M | - | - |
| Depreciation | 0.49M | - | 0.39M | 0.18M | 0.12M |
| Other cashflows from investing activities | -0.62M | -0.30M | -0.03M | - | -0.01M |
| Dividends paid | 0.90M | 1.82M | 1.08M | 0.60M | 0.17M |
| Change to inventory | -1.59M | -1.03M | -0.55M | -0.53M | -0.04M |
| Change to account receivables | -0.40M | -1.84M | -1.29M | 0.91M | -0.11M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -0.36M | 0.00M | -0.35M | -0.16M | -0.10M |
| Change to netincome | - | - | - | -0.04M | 0.16M |
| Capital expenditures | 0.03M | 0.26M | 0.41M | 0.10M | 0.01M |
| Change in working capital | -7.05M | -4.58M | -1.16M | 0.24M | 0.31M |
| Stock based compensation | - | - | 0.02M | 0.18M | 0.16M |
| Other non cash items | 3.12M | 8.93M | -0.06M | 0.17M | -0.24M |
| Free cash flow | -8.79M | 4.09M | 5.73M | 3.91M | -0.01M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EZZ EZZ Life Science Holdings Ltd |
-0.01 1.64% |
0.30 | - | - | 0.31 | 0.59 | 0.11 | 0.78 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 4.82 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 3.85 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 31.95 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | 18.28 | -9.86 |
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, South-East Asia, and internationally. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides health and wellness products under the EZZ brand. It also offers its products online. The company was incorporated in 2015 and is based in Lidcombe, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Qin | Co-founder, COO, Interim CEO & Exec. Director | NA |
| Anthony Guarna | Chief Financial Officer | NA |
| Ms. Natalie Climo L.L.B. | Company Sec. | NA |
| Mr. Mark Qin | Co-founder, COO, CEO & Executive Director | NA |
| Ms. Natalie Climo L.L.B. | Company Secretary | NA |
| Mr. Mark Qin | Co-founder, COO, CEO & Executive Director | NA |
| Ms. Natalie Climo L.L.B. | Company Secretary | NA |
| Mr. Mark Qin | Co-founder, COO, CEO & Executive Director | NA |
| Ms. Natalie Climo L.L.B. | Company Secretary | NA |
| Mr. Mark Qin | Co-founder, COO, CEO & Executive Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.